Skip to content
Open access

Effect of Apremilast in the treatment and prevention of allergic contact dermatitis in a DPCP-induced rat model

2026 · Tropical Journal of Pharmaceutical Research · 0 citations

Abstract

Purpose: To investigate the anti-inflammatory effect of apremilast in diphenylcyclopropenone (DPCP)-induced allergic contact dermatitis model in rats.Methods: A total of 40 adult male rats were randomly assigned into five groups (n = 8). Group 1 was the negative control; group 2 was induced with diphenylcyclopropenone (DPCP) 2 %; groups 3, 4, and 5 were induced with DPCP and treated with apremilast (20 mg/kg), pre-treated with apremilast (20 mg/kg), and dexamethasone (1 mg/kg), respectively. Systemic cytokine levels were quantified after sensitization and challenge phase with DPCP using an enzyme-linked immunosorbent assay (ELISA) kit, and histoarchitecture of the skin was examined using hematoxylin – eosin (H & E) staining.Results: Induction with DPCP was associated with significant elevation in TNF-α and IL-1β levels compared to negative control (p < 0.01). Apremilast administration, both as treatment and prophylaxis, significantly reduced IL-1β (p < 0.01) and TNF-α (p < 0.05). Furthermore, dexamethasone significantly reduced IL-1β levels only slightly (p < 0.05) with no significant effect on TNF-α (p > 0.05).Conclusion: Apremilast administration significantly reduced levels of inflammatory markers compared to dexamethasone.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.